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Myeloma cells are dependent on signals from the bone
marrow micro-environment for proliferation and survival
(1). Myeloma cell growth factors mediate redundant
effects since one growth factor can substitute for another
in vitro (2, 3). This observation led us to hypothesize that
intracellular signals generated by myeloma growth
factors target common genes important for growth and
survival of myeloma cells. These genes may represent
potential drug targets. Microarray experiments done in
our laboratory showed that the myeloma cell growth fac-
tors interleukin (IL)-6, IL-21 and tumor necrosis factor
(TNF)-a all induced expression of the putative oncogene
BCL3 in the myeloma cell lines IH-1 and OH-2 (paper in
preparation). These data supported previous studies done
by Brocke-Heidrich et al. and Tsuyama et al., who
showed that BCL3 is upregulated by IL-6 at mRNA
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6). However, the expression of BCL3 in myeloma patient
samples has not been studied. Based on this we decided
to study the role of BCL3 in primary myeloma cells as
well as in myeloma cell lines in more detail.
BCL3 was ﬁrst identiﬁed through its involvement in
the t (14;19) (q32;q13) translocation in B-cell chronic
lymphocytic leukemia (CLL) (7). Leukemic cells from
these patients had increased levels of BCL3 mRNA,
leading to the hypothesis that BCL3 is a proto-oncogene
contributing to leukemogenesis (8). BCL3 is overexpres-
sed in breast cancers, subtypes of lymphomas and naso-
pharyngeal carcinomas (9–12). Supporting the notion
that BCL3 is an oncogene, Viatour et al. demonstrated
that overexpression of BCL3 is sufﬁcient to transform
the mouse ﬁbroblast cell line NIH3T3 and induce tumor
growth subcutaneously in nude mice (13). Physiologi-
cally, BCL3 has been implicated to play a role during
B-cell development and as a negative regulator of
immune responses (14–16).
BCL3 encodes a protein denoted Bcl-3 that is a mem-
ber of the inhibitory jB( I jB)-family (17, 18). The IjB
proteins modulate the DNA-binding activity of nuclear
factor-jB (NFjB), a family of transcription factors
involved in apoptosis and cell growth (19). Activation of
NFjB is implicated as an important mechanism for the
development of antiapoptosis and drug resistance in mul-
tiple myeloma (20). Depending on context, Bcl-3 either
activates or inhibits NFjB-dependent gene transcription
through interactions with homodimers of NFjB p50 or
p52 (14, 21–26). We here present evidence that BCL3 is
overexpressed in myeloma cells from a subset of mye-
loma patients, and that the high expression of BCL3 at
the time of diagnosis is associated with inferior progno-
sis. Furthermore, high expression of Bcl-3 in myeloma
cell lines induced by growth-promoting cytokines is asso-
ciated with increased proliferation of the cells. We
propose that Bcl-3 contributes to regulation of NFjB-
dependent gene transcription in myeloma cells, with
potential oncogenic consequences.
Materials and methods
Cell lines and culture conditions
The human myeloma cell line ANBL-6 (gift from Dr
D. Jelinek, Mayo Clinic, Rochester, MN, USA), IH-1
(3), INA-6 (gift from Dr M. Gramatzki, Erlangen,
Germany), JJN-3 (gift from Dr J. Ball, Department of
Immunology, University of Birmingham, UK), OH-2
(2), RPMI-8226 and U-266 (both from American Type
Culture Collection, Rockville, MD, USA) were cultured
as previously described (27). The CAG cell line (gift
from Dr J Epstein, Little Rock, AK, USA) was grown
in RPMI 1640 (Gibco, Paisley, UK) supplemented with
l-glutamine 100 lg⁄mL, gentamicin 20 lg⁄mL (referred
to as RPMI) and 10% heat inactivated fetal calf serum
(FCS; HyClone, Logan, UT, USA). The cells were
kept at 37 C in a humidiﬁed atmosphere containing
5% CO2, and were washed four times in Hanks‘
balanced salt solution (HBSS; Gibco, Paisley, UK) to
deplete them of serum and cytokines before performing
experiments.
Patients and healthy individuals; separation of CD138
+
plasma cells
Gene expression proﬁles (GEP) were studied in plasma
cells from 351 patients with newly diagnosed multiple
myeloma (MM), 12 patients with smouldering multiple
myeloma (SMM), 44 patients with monoclonal gammop-
athy of undetermined signiﬁcance (MGUS) and 22
healthy individuals. The patients were recruited from
University of Arkansas for Medical Sciences, Little
Rock, USA, and the use of patient samples in research
studies was approved by the University of Arkansas for
Medical Sciences (Little Rock, AR) Institutional Review
Board. Details about classiﬁcation of these patients have
been previously described (28, 29).
We used patient samples from the Norwegian
Research Biobank for multiple myeloma for studies of
Bcl-3 expression by RT-PCR (10 patients) immunohisto-
chemistry (18 patients with MM and three patients with
plasmocytoma), Western blot (eight patients) and cIg-
FISH (19 patients). The Norwegian Research Biobank
for multiple myleoma has been approved by the Regio-
nal Ethics Committee of Middle Norway and Norwegian
Health Authorities. All patients have signed informed
consent to store samples in the Biobank and to use sam-
ples for research purposes. Separation of plasma cells
before GEP was done as previously described (28).
Cytokines and antibodies
IL-6 was purchased from Biosource (Camarillo, CA,
USA). IL-10, IL-15 and insulin-like growth factor (IGF)-
1 were from R&D systems (Abingdon, UK). TNF-a was
from Genetech (South San Francisco, CA, USA), and
IL-21 was a gift from R.Holly, ZymoGenetics (Seattle,
WA, USA). Hepatocyte growth factor (HGF) was puri-
ﬁed from a medium conditioned by JJN-3 as described
previously (30). All cytokines except HGF were of
recombinant human type. Polyclonal anti-Bcl-3 (sc-185),
polyclonal anti-p65 (sc-109) and monoclonal anti-p50
(sc-8414) for Western blotting were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Monoclonal anti-GAPDH and anti-Lamin B used as
loading controls on Western blots were purchased from
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(Cat#NA12; Darmstadt, Germany), respectively.
Preparation of cRNA and microarray hybridization
RNA, cRNA preparation and hybridization to U133
Plus2 GeneChip microarrays (Affymetrix, Santa Clara,
CA, USA) were performed as previously described (31).
Statistical analysis
Gene expression was analyzed as previously described
(28, 31). Differences in expression of BCL3 between
plasma cells from MM patients and normal plasma cells
(NPC) were analyzed using One-Way anova test. Sur-
vival distributions were presented with the use of the
Kaplan–Meier method and compared with the log-rank
test. Statistical tests were performed with the software
package spss 12.0 (SPSS, Chicago, IL, USA).
Analysis of BCL3 expression by quantitative real-time
PCR (qPCR)
Plasma cells from 10 patients were isolated with CD138
antibodies conjugated to magnetic beads using a RoboSep
(StemCell Technologies, Vancouver, BC, Canada) cell sep-
aration device. Total RNA isolated using the MirVana
 
miRNA Isolation Kit (Applied Biosystems, Foster City,
CA, USA). cDNA was synthesized using Taqman reverse
transcriptase reagents from Roche-Applied Biosystems.
qPCR of BCL3 was performed using StepOne Real-Time
PCR System, (Applied Biosystems). BCL3 TaqMan pri-
mer (Hs00180403_m1, Taqman, Gene Expression Assays,
Applied Biosystems) was used to detect BCL3 expression.
The comparative Ct-method was used for quantization
with GAPDH (HS99999905_m1) as housekeeping gene.
Western blotting
Cells (1.2 · 10
6) were seeded in 3 mL RPMI supple-
mented with 0.1% bovine serum albumin (BSA, Sigma-
Aldrich, St. Louis, MO, USA) before Western blotting of
whole cell lysates. The ANBL-6, IH-1, INA-6 and OH-2
cell lines were starved overnight before they were stimu-
lated with cytokines as indicated at time point 0 (T0). At
this time point, cells that were not stimulated with cyto-
kines were harvested. The viability of these cells as mea-
sured by propidium iodide-staining was 60–80%, similar
to the viability of cells grown in IL-6 enriched medium.
CAG, JJN-3, RPMI-8226 and U-266 were stimulated
with IL-6 immediately after seeding or left without cyto-
kines in RPMI with 0.1% BSA for 24 h. After harvesting,
dry pellets were kept at )80 C until further processing.
Pellets were lysed in lysis buffer (10% sodium dodecyl
sulfate, 10 mm Tris-HCL, pH 6.8) at 50 C using a Hamil-
ton injector, mixed with NuPage LDS sample buffer (In-
vitrogen, Carlsbad, CA, USA) containing 0.1 m
dithiothreitol, and heated for 2 min at 90 C. The lysates
(40 lg of proteins) were then separated on 10% NuPage
Bis-Tris gels (Invitrogen), followed by electrophoretic
transfer to nitrocellulose membranes (Bio-Rad, Hercules,
CA, USA). Membranes were blocked in 50 mm Tris buf-
fered saline pH 7.5 containing 0.05% Tween 20 and 5%
non-fat dried milk (Nestle, Vevey, Switzerland) and incu-
bated with antibodies as indicated. After incubation with
horseradish peroxidase-conjugated secondary antibodies
(DakoCytomation, Glostrup, Denmark), the proteins
were visualized by ECL Western blotting detection
reagents (Amersham Biosciences, Buckinghamshire, UK),
scanned (Canoscan D1250 U25, Canon Europa NV, Am-
stelveen, The Netherlands) and imported into adobe
photoshop elements 4.0 software (Adobe Systems Inc,
San Jose, CA, USA) for image acquisition. Cytosol-and
nuclear extracts of IH-1 were prepared using Active
Motifs nuclear extract kit (Active Motif, CA, USA)
according to the manufacturer’s protocol. These cells
were seeded in RPMI containing 10% FCS and cyto-
kines as indicated for 24 h without previous starvation of
cells.
Thymidine incorporation assays
To measure DNA synthesis, cells were seeded in triplets
in 96-well cell culture plates (Corning Inc, Corning, NY,
USA) at a density of 2 · 10
4 cells per well in RPMI sup-
plemented with 0.1% BSA and cytokines as indicated.
ANBL-6, IH-1,INA-6 and OH-2 were pulsed with
0.75 lCi methyl-[
3H]-thymidine (NEN Life Science prod-
ucts, Boston, MA, USA) after 30 h of stimulation with
cytokines and harvested 18 h later using a Micromate
96-well harvester (Packard, Meriden, CT, USA). CAG,
JJN-3, RPMI-8226 and U-266 were pulsed with 0.75 lCi
methyl-[
3H]-thymidine for 4 h after 24 h of stimulation.
Figure 1 Protein expression of Bcl-3 in myeloma cell lines and corresponding cell proliferation after cytokine stimulation. Bcl-3 expression in
whole cell lysates and corresponding myeloma cell proliferation. The same cytokine concentrations were used for Western blot as for [
3H]-thymi-
dine incorporation assay. Average counts per minute (CPM⁄AVG) are plotted along the y-axis on graph. Bars represent mean + SD of triplicate
wells. (A) IL-6 dependent myeloma cell lines (IH-1, OH-2, ANBL-6, INA-6) were harvested after overnight starvation (T0) or stimulated with cyto-
kines as indicated for 4 and 24 h. (B) IL-6-independent myeloma cell lines (CAG, JJN-3, RPMI-8226, U-266) were stimulated with IL-6 or left
unstimulated for 24 h. GAPDH was used as loading control.
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(Packard).
Immunohistochemistry
Sections (4 lm) of formalin-ﬁxed bone marrow biopsies
were prepared and visualized as previously described
(32). The sections were incubated with a monoclonal
antibody speciﬁc for Bcl-3 (clone 1E8, Novocastra, New-
castle upon Tyne, UK) at a dilution of 1 : 25. Parallel
sections were stained with anti CD138 (Dako, code no.
M7228, clone MI 15, dilution 1 : 100). Only CD138
+
cells were considered and the biopsies were deﬁned as
Bcl3
+ when ‡20% of the CD138
+ cells was stained.
Cytoplasmic immunoglobulin ﬂuorescence in situ
hybridization (cIg-FISH)
Cytospin of Lymphoprep-separated (Dynal, Oslo,
Norway) bone marrow mononuclear cells from MM
patients were ﬁxed in acetic acid⁄methanol (1:3 v⁄v,
)20 C, 40 min) and air-dried. 5 lLo fBCL3 split probe
(No.Y5411; DakoCytomation) was applied and the slide
was sealed with coverslip and rubber cement. Hybridiza-
tion was done in a Dako Hybridizer according to the
manufacturer’s protocol. The cells were then incubated
with 15% goat serum in phosphate buffered saline.
Plasma cells were labeled with AMCA (7-amino-4-meth-
ylcoumarin-3-acetic acid)-conjugated anti-human IgG
against cytoplasmic j⁄k-chains (Vector Laboratories,
Burlingame, CA, USA). The slides were air dried in the
dark before anti-fade (Vectashield had-set mounting
medium without DAPI, Vector Laboratories) was added.
The cells were scored as previously described (32). Nor-
mal locus was detected as a colocalization of red and
green signal, and a split was detected as separate red and
green signal.
Assessment of NFjB activity
Activation of the NFjB family members can be mea-
sured by their capacity to bind to consensus DNA bind-
ing sites (33). We used the TransAm NFjB p65 and p50
transcription Factor Assay Kit (Active Motif, CA, USA)
to quantify the DNA binding activity of p50 and p65.
The assay was performed according to the manufac-
turer’s protocol. Brieﬂy, IH-1 cells were cultured for 24 h
without previous starvation in RPMI containing 10%
FCS and cytokines as indicated. Nuclear extracts were
prepared and incubated in 96-well plates coated with an
immobilized oligonucleotide containing the 5‘-
GGACTTTCC-3‘ consensus binding site for NFjB.
Hybridization to the target oligonucleotide was detected
by incubation with primary antibodies speciﬁc for p65 of
p50, visualized by anti-IgG1-HRP and quantiﬁed at
450 nm. Speciﬁcity was conﬁrmed by incubating with a
wild type consensus oligonucleotide that competed with
the substrate for binding to the immobilized oligo-
nucleotide.
Results
Growth promoting cytokines induce Bcl-3 in myeloma
cell lines
We stimulated the IL-6-dependent myeloma cell lines
ANBL-6, IH-1, INA-6 and OH-2 with cytokines known
to promote growth of myeloma cells (2, 3, 34–37). The
cytokines were given in optimal concentrations for
growth. Protein expression of Bcl-3 increased in these cell
lines after 4 h of cytokine stimulation compared with
baseline level, and increased even more after 24 h of
stimulation (Fig. 1A). IL-6, IL-21 and TNF-a were the
most potent inducers of Bcl-3. Cytokines that induced
Bcl-3 also induced proliferation of the corresponding
myeloma cell line (Fig. 1A). However, there were a few
exceptions from this association. In ANBL-6, TNF-a
increased the level of Bcl-3 without stimulating prolifera-
tion, whereas IGF-1 induced proliferation without
increasing Bcl-3 expression. We also tested the effect of
IL-6 on Bcl-3 expression in the IL-6 independent cell
lines CAG, RPMI-8226, U-266 and JJN-3. Bcl-3 was
induced in the cell lines where IL-6 gave a proliferative
response. JJN-3 had constitutive expression of Bcl-3, and
in this cell line IL-6 had no effect on Bcl-3 expression
(Fig. 1B).
Expression of BCL3 in CD 138
+ bone marrow plasma
cells from MM patients is associated with poor
outcome
We studied GEP of CD138
+ bone marrow plasma cells
from 351 newly diagnosed MM patients, 22 healthy indi-
viduals, 44 patients with MGUS and 12 patients with
SMM. Based on ‘present’ detection call, BCL3 was pres-
ent in 229 (65%) of MM plasma cell samples and in 11
(46%) of normal plasma cell samples (NPC; data not
shown). By further comparison of BCL3 expression
between NPC and primary MMs based on absolute inten-
sity signal, there was no signiﬁcant difference in BCL3
expression (median 445 (range: 23–2555) in MM plasma
cells vs. median 534 (range: 41–970) in NPC, P = 0.7).
However, when the expression of BCL3 among NPC,
MGUS, SMM, and MM subgroups was compared, the
level of BCL3 was signiﬁcantly increased in one of the
gene expression-deﬁned high-risk subgroups, namely the
PR (proliferation) subgroup (Fig. 2A) (28). When looking
at outcome, Kaplan–Meier analysis revealed 5-yr event-
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+ MM plasma cells. (A) Box plot of BCL3 expression in NPC and in plasma cells from
patients with MGUS, SMM and overt MM. The expression level of BCL3 is in addition shown for subgroups of MM patients based on molecular
classiﬁcation. Sample groups are along the x-axis and the natural log transformed Affymetrix-derived signal is plotted on the y-axis. The top, bot-
tom and middle lines of each box correspond to the 75th percentile (top quartile), 25th percentile (bottom quartile) and 50th percentile (median),
respectively. The whiskers extend from the 10th percentile (bottom decile) and 90th percentile (top decile). Open circles denote outliers within
each group. The P-value states that BCL3 was signiﬁcantly increased in the proliferation subgroup (PR) compared with the other subgroups as
well as to the NPC, MGUS and SMM groups. MY, all MM patients; LB, low bone disease subgroup; MS, MMSET subgroup; HY, hyperdiploid
subgroup; CD-1, CCND1 subgroup: CD-2, CCND3 subgroup: MF, MAF⁄MAFB subgroup. (B) and (C) Kaplan–Meier 5 yr estimates of EFS and OS
showed inferior EFS and OS of MM patients with BCL3 expression levels above 75th percentile(top quartile). (D) Bcl-3 was detected in bone mar-
row biopsies by immunohistochemistry. The bone marrow biopsy illustrated here had an overall 20% Bcl-3
+ plasma cells. (E) MM patient with an
unbalanced BCL3 translocation detected by cIg-FISH. The red signal is upstream and the green signal is downstream of the BCL3 gene. Colocal-
ization of the signals represents normal genes, while a single green signal represents an unbalanced translocation.
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yr overall survival estimates of 42% (OS, P = 0.0030)
among 88 patients with BCL3 expression above 75th per-
centile, compared with 52% and 72% among the other
263 patients respectively (Figs 2B and 2C). Our study
population of myeloma patients was uniformly treated
with tandem transplants (28).
Bcl-3 is detected at mRNA and protein level in plasma
cells from MM patients
Expression of BCL3 mRNA was studied by qPCR in
samples from 10 randomly selected MM patients
(Figure S1). All patients expressed BCL3, with six of the
patients expressing four times or more the amount com-
pared to the patient with the lowest expression level, con-
ﬁrming the Affymetrix data showing that a subset of
MM patients expresses high amounts of BCL3. Expres-
sion of Bcl-3 at protein level was examined by two inde-
pendent methods, immunohistochemistry in bone
marrow biopsies and Western blot of puriﬁed myeloma
cells. Of 18 newly diagnosed MM patients and in biop-
sies from three plasmocytoma patients, two biopsies (one
bone marrow biopsy from a MM patient and one
plasmocytoma biopsy) were positive for Bcl-3, with 20%
and 40% Bcl-3+plasma cells, respectively (Fig. 2D). In
addition, one MM bone marrow biopsy had 5–10% of
Bcl3
+ plasma cells. When looking at the Bcl-3 protein
expression in CD138
+ plasma cells from eight myeloma
patients, we detected Bcl-3 in seven of eight samples with
Western blot (data not shown).
The BCL3 gene is altered in malignant plasma cells
from MM patients
To reveal whether alterations in the BCL3 gene locus
could explain the upregulation of Bcl-3 in malignant
plasma cells from MM patients, we examined bone mar-
row aspirates from 19 newly diagnosed MM patients
using cIg-FISH and a commercial BCL3 split probe. We
found that four patients had an extra copy of the BCL3
gene (data not shown). In addition, one t (4;14)
+ patient
had an unbalanced translocation involving an extra copy
of the BCL3 locus (Fig. 2E).
Intracellular localization of Bcl-3 is dependent on type
of stimulus given to the cell
To be activated, Bcl-3 is translocated to the nucleus of
the cells (26). We wanted to study if Bcl-3 is a nuclear
protein in myeloma cells. We used IH-1 as a model cell
line since Bcl-3 was highly inducible by cytokines in this
cell line (Fig. 1A). After stimulation with IL-6, Bcl-3 was
detected in the nuclear fraction of IH-1 (Fig. 3A). By
contrast, Bcl-3 was detected only in the cytosolic fraction
of TNF-a-stimulated cells. Both IL-6 and TNF-a have a
proliferative effect on myeloma cells (Fig. 1A).
Bcl-3 has been shown to associate with homodimers of
NFjB p50 or p52 in the nucleus and repress DNA-bind-
ing of p50⁄p65, the classical NFjB dimer activated by
TNF-a (14, 21–26, 38). We therefore examined the intra-
cellular localization of NFjB p50 and p65 in IH-1 after
IL-6 and TNF-a stimulation, as well as their DNA-
binding capacity under these conditions. We found that
both these proteins were present in the nucleus after
TNF-a and IL-6 stimulation (Fig. 3A). However, while
TNF-a activated both p65 and p50, IL-6 activated p50
only (Fig. 3B). Hence, after IL-6 stimulation, p50 was
activated, and this activation coincided with nuclear
presence of Bcl-3. Simultaneously, there was a lack of
p65 activation.
Figure 3 Intracellular localization of Bcl-3 and activation of NFjB p50
and p65. (A) Bcl-3 was detected on Western blot in the nuclear frac-
tion of IL-6-stimulated IH-1 cells, but was absent in the nuclear frac-
tion of TNF-a- and unstimulated cells. The NFjB proteins p50 and p65
were present in all conditions. GAPDH was used as loading control.
Presence of GAPDH in the nucleus is earlier reported (43). Lamin B
was used to determine the purity of the extracts. (B) Activation of
NFjB p50 in nuclear extracts of IH-1 after IL-6 stimulation, and p50
and p65 after TNF-a-stimulation. Bars represent mean + SD of dupli-
cate wells. The y-axis denotes optical density (OD) at 450 nm. The
experiments were repeated three times.
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This work shows for the ﬁrst time that myeloma cells
from MM patients express BCL3 and that high expres-
sion of BCL3 at the time of diagnosis is associated with
reduced survival. Furthermore, in a comparison of
molecularly deﬁned subgroups, BCL3 expression was sig-
niﬁcantly increased in a high risk subgroup characterized
by overexpression of cell cycle-and proliferation-related
genes (28). Our data are consistent with the concept that
high BCL3 expression is an event associated with poor
outcome.
We have not shown that BCL3 is an independent
adverse prognostic factor and the exact relevance of ele-
vated expression of BCL3 in myeloma high-risk disease
is currently unclear. Interestingly, Annunziata et al. has
shown that the high risk subgroup with high expression
of BCL3 has a very low average expression of NFjB sig-
nature genes (39). NFjB signature genes are genes that
are activated by the classical and⁄or alternative NFjB
pathway (39). It is therefore tempting to speculate that
the nuclear presence of Bcl-3 as after IL-6 stimulation
activates a different set of genes than activation of the
classical and⁄or alternative NFjB pathway in myeloma
cells.
The array data was conﬁrmed with qPCR in a material
with 10 patients. In another randomly selected material
with eight patients with MM, Bcl-3 protein was detected
in seven of eight samples by Western blot. We also exam-
ined the expression of Bcl-3 at protein level by immuno-
histochemical staining of biopsies from MM patients and
patients with plasmacytoma, and found that 11% (two of
18) of the biopsies stained positive for Bcl-3. This propor-
tion of Bcl-3
+ plasma cell malignancies is similar to the
proportion of B-cell lymphomas expressing Bcl-3 (6%)
(9). The discrepancy between the proportion of patient
samples positive for BCL3 at mRNA level and biopsies
positive for Bcl-3 at protein level may be caused by lower
sensitivity of immunostaining of biopsies, a well-known
problem when using immunohistochemistry as detection
method. However, the number of patient samples tested
was small, and we cannot rule out that there is reduced
translation or post-translational modiﬁcations.
Our data showed that stimulation of myeloma cells
with various cytokines well-known to promote prolifera-
tion increased Bcl-3 expression. These data indicate that
the gene encoding Bcl-3 is indeed a common target gene
for growth promoting cytokines in myeloma cells. As
growth-promoting cytokines are frequently present in the
bone marrow of MM patients, cytokine signaling is a
highly possible mechanism for upregulation of Bcl-3 in
myeloma cells in vivo. Importantly, and in concordance
with the patient data, we found that the induction of
Bcl-3 by cytokines was associated with increased prolifer-
ation of myeloma cells. However, in line with the results
from Brocke-Heidrich et al. (5), we could not show any
effect on thymidine incorporation or apoptosis when
down regulating Bcl-3 with siRNA in the INA-6 cell line
(data not shown). These results are from only one cell
line and further studies are needed to clarify the exact
role of Bcl-3.
Additional potential mechanisms for upregulation of
Bcl-3 in MM patients are gains⁄ampliﬁcation of the BCL3
gene, as described in patients with anaplastic large cell
lymphoma, or translocations involving chromosome 19, as
found in patients with CLL (40, 41). Our studies substanti-
ate that both these mechanism may be active in freshly iso-
lated MM patients cells. The BCL3 gene is located at
chromosome 19, a chromosome with frequent trisomy in
MM patients having a hyperdiploid tumor (42).
In our study, intracellular localization of Bcl-3 was
dependent of type of stimulus given to the cell. Nuclear
accumulation of Bcl-3, as after IL-6 stimulation, has
been shown to be associated with p50⁄Bcl-3- or p52⁄Bcl-
3 dependent gene activation and subsequent proliferation
in CYLD-lacking keratinocytes (26). It is possible that
similar mechanisms are active in myeloma cells, and may
explain why we observed activation of p50 in IH-1 after
IL-6 stimulation.
The starting point of this study was our observation
that IL-6, IL-21 and TNF-a induced expression of BCL3
in the myeloma cell lines OH-2 and IH-1. Our study
demonstrates that also the protein, Bcl-3, is produced in
cell lines by cytokine stimulation and is associated with
increased proliferation of the cells. We show for the ﬁrst
time that Bcl-3 is present in a subset of MM patients,
and that the high gene expression at the time of diagno-
sis is associated with inferior prognosis as demonstrated
in a large cohort of newly diagnosed patients. Our results
indicate a potential role for Bcl-3 in the development
of multiple myeloma, and further studies are needed to
clarify this.
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